NILOTINIB

Generic: NILOTINIB

Cipla USA Inc.Manufacturer
ORALRoute
NILOTINIBActive Substance
2025-02-19Original Approval

NILOTINIB is FDA application NDA218922, sponsored by CIPLA. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.

Recalls

Top Reported Reactions

1
DRUG INTOLERANCE
430 reports
2
DRUG INEFFECTIVE
349 reports
3
DRUG RESISTANCE
348 reports
4
DIARRHOEA
338 reports
5
DYSPNOEA
335 reports
6
FATIGUE
325 reports
7
NAUSEA
306 reports
8
HEADACHE
302 reports
9
MYALGIA
281 reports
10
ARTHRALGIA
272 reports